Key highlights
26 October 2023 – 1 mins read
LinkedIn
Twitter
Facebook
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023.
Filter
Period
Filter by
recent search
Showing: 1 – 05 of 23 Financial Results
13 February 2020
LinkedIn
Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook
Aymeric Le Chatelier, Chief Executive Officer and Chief Financial Officer of Ipsen, stated: “2019 was another excellent year of operating performance for Ipsen with continued double-digit top-line growth and core operating margin expansion. Despite the recent palovarotene setback, the fundamentals of…
24 October 2019
LinkedIn
Ipsen delivers strong double-digit sales growth for the third quarter of 2019 and confirms full year 2019 guidance
Unaudited IFRS consolidated sales
25 July 2019
LinkedIn
Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019
Extract of audited consolidated results for H1 2019 and 2018
24 April 2019
LinkedIn
Ipsen reports strong double-digit sales growth in First Quarter 2019 and confirms Full Year 2019 financial targets
First quarter 2019 unaudited IFRS consolidated sales
25 October 2018
Your dedicated contacts
-
Craig Marks
Vice President, Investor Relations
-
-
Nicolas Bogler
Senior Manager, Investor Relations
-